

Rachel P Rosovsky

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3541101/rachel-p-rosovsky-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91
papers

2,757
citations

20
h-index

52
g-index

123
ext. papers

3,861
ext. citations

6.3
avg, IF

5.16
L-index

#	Paper	IF	Citations
91	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.. <i>JAMA Network Open</i> , 2022 , 5, e2142046	10.4	1
90	COVID-19 and venous thromboembolism: A narrative review.. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022 , 6, e12666	5.1	2
89	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e224304	10.4	4
88	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment.. <i>Contemporary Clinical Trials</i> , 2022 , 115, 106714	2.3	1
87	173: NOVEL COAGULATION TEST SUCCESSFULLY DETECTS ANTICOAGULATION RESISTANCE IN PATIENTS WITH COVID-19. <i>Critical Care Medicine</i> , 2022 , 50, 70-70	1.4	
86	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2022.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022 , 20, 436-442	7.3	2
85	Sex Differences in Presentation, Risk Factors, Drug and Interventional Therapies, and Outcomes of Elderly Patients with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study.. <i>Thrombosis Research</i> , 2022 , 214, 122-131	8.2	0
84	Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. <i>Blood Cancer Journal</i> , 2021 , 11, 176	7	3
83	Pulmonary Hypertension Is Associated with Poor Outcomes in Patients with Myeloproliferative Neoplasms and Cardiovascular Disease. <i>Blood</i> , 2021 , 138, 3653-3653	2.2	0
82	Bleeding Complications in Patients with Cancer and COVID 19- Analysis from the COVID 19 and Cancer Consortium (CCC19) Registry. <i>Blood</i> , 2021 , 138, 4997-4997	2.2	
81	High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients. <i>Blood</i> , 2021 , 138, 3632-3632	2.2	0
80	Increased Risk of Thrombosis in Patients with Myeloproliferative Neoplasms Compared with the General Population Hospitalized with COVID-19. <i>Blood</i> , 2021 , 138, 1508-1508	2.2	
79	North American Physician Practice Patterns in the Management of Anticoagulation in Pregnancy. <i>Journal of Women's Health</i> , 2021 , 30, 829-836	3	1
78	Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021 , 9, 835-844. 32	3.2	8
77	Venous Thromboembolism: Genetics and Thrombophilias. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2021 , 42, 271-283	3.9	0
76	Case of right ventricular and aortic thrombi in a patient with severe COVID-19. <i>BMJ Case Reports</i> , 2021 , 14,	0.9	1
75	Temporal Trends in Inpatient Oncology Census Before and During the COVID-19 Pandemic and Rates of Nosocomial COVID-19 Among Patients with Cancer at a Large Academic Center. <i>Oncologist</i> , 2021 , 26, e1427-e1433	5.7	3

74	Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. <i>Oncologist</i> , 2021 , 26, 685-693	5.7	1
73	Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19. <i>Annals of Internal Medicine</i> , 2021 , 174, 622-632	8	41
72	Interhospital Transfer of Patients With Acute Pulmonary Embolism: Challenges and Opportunities. <i>Chest</i> , 2021 , 160, 1844-1852	5.3	3
71	Deep vein thrombosis protocol optimization to minimize healthcare worker exposure in coronavirus disease-2019. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021 , 9, 299-306	3.2	7
70	Filter clotting with continuous renal replacement therapy in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 966-970	5.1	7
69	Prediction and Prevention of Cancer-Associated Thromboembolism. <i>Oncologist</i> , 2021 , 26, e2-e7	5.7	12
68	Evaluation of direct thrombin inhibitors during a critical heparin shortage. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 662-673	5.1	
67	Association of Thrombosis With Hypereosinophilic Syndrome in Patients With Genetic Alterations. <i>JAMA Network Open</i> , 2021 , 4, e2119812	10.4	1
66	The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2522-2532	15.4	6
65	Comparison of Published Guidelines for the Diagnosis and the Management of Vaccine-Induced Immune Thrombotic Thrombocytopenia 2021 , 3, e0519		3
64	Nuts and bolts of COVID-19 associated coagulopathy: the essentials for management and treatment. <i>Postgraduate Medicine</i> , 2021 , 133, 899-911	3.7	2
63	Interhospital Transfer for the Management of Acute Pulmonary Embolism.. <i>American Journal of Medicine</i> , 2021 ,	2.4	2
62	A clinical decision framework to guide the outpatient treatment of emergency department patients diagnosed with acute pulmonary embolism or deep vein thrombosis: Results from a multidisciplinary consensus panel.. <i>Journal of the American College of Emergency Physicians Open</i> , 2021 , 2, e12588	1.6	
61	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020 , 38, 761-766	24.3	12
60	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1128-1136	7	43
59	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	41.8880	
58	Special Considerations in Pulmonary Embolism: Clot-in-Transit and Incidental Pulmonary Embolism. <i>Critical Care Clinics</i> , 2020 , 36, 531-546	4.5	5
57	COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. <i>Blood</i> , 2020 , 136, 489-500	2.2	642

56	When Pigs Fly: A Multidisciplinary Approach to Navigating a Critical Heparin Shortage. <i>Oncologist</i> , 2020 , 25, 334-347	5.7	4
55	Anticoagulation Practice Patterns in COVID-19: A Global Survey. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 969	5.1	27
54	A comprehensive evaluation of apixaban in the treatment of venous thromboembolism. <i>Expert Review of Hematology</i> , 2020 , 13, 155-173	2.8	3
53	Incidence and Outcomes of Heparin-Induced Thrombocytopenia Associated with a Heparin Shortage at a Large Academic Medical Center. <i>Blood</i> , 2020 , 136, 10-10	2.2	
52	Filter Clotting with Continuous Renal Replacement Therapy in COVID-19. <i>Blood</i> , 2020 , 136, 22-23	2.2	
51	Rates of Thrombotic Events in Hypereosinophilic Syndrome and the Effect of Molecular Aberrations in Thrombotic Risk. <i>Blood</i> , 2020 , 136, 14-14	2.2	
50	Evaluation of the Prothrombin Fragment 1.2 in Patients with COVID-19. <i>Blood</i> , 2020 , 136, 4-5	2.2	
49	NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 12-22	7.3	44
48	Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 1-4	7.3	16
47	Treatment for Pulmonary Embolism: Anticoagulation Selection and Duration. <i>Respiratory Medicine</i> , 2020 , 57-83	0.2	
46	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. <i>Annals of Emergency Medicine</i> , 2020 , 76, 470-485	2.1	18
45	Analysis of Partial Thromboplastin Times in Patients With Pulmonary Embolism During the First 48 Hours of Anticoagulation With Unfractionated Heparin. <i>Academic Emergency Medicine</i> , 2020 , 27, 117-127 ^{3,4}		8
44	Anticoagulant acrobatics: Surviving the global heparin shortage in the emergency department. <i>American Journal of Emergency Medicine</i> , 2020 , 38, 1291-1293	2.9	
43	A low dose heparinized saline protocol is associated with improved duration of arterial line patency in critically ill COVID-19 patients. <i>Journal of Critical Care</i> , 2020 , 60, 253-259	4	4
42	Case 35-2020: A 59-Year-Old Woman with Type 1 Diabetes Mellitus and Obtundation. <i>New England Journal of Medicine</i> , 2020 , 383, 1974-1983	59.2	0
41	The Art of Oncology: COVID-19 Era. <i>Oncologist</i> , 2020 , 25, 997-1000g	5.7	3
40	Diagnosis and Treatment of Pulmonary Embolism During the Coronavirus Disease 2019 Pandemic: A Position Paper From the National PERT Consortium. <i>Chest</i> , 2020 , 158, 2590-2601	5.3	37
39	Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations. <i>Critical Care</i> , 2020 , 24, 559	10.8	44

38	Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19). <i>American Journal of Hematology</i> , 2020 , 95, 1479-1485	7.1	13
37	Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1637-1647	15.4	37
36	A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. <i>Blood Advances</i> , 2020 , 4, 9-18	7.8	26
35	Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019 , 3, 315-330	5.1	31
34	Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619853037	3.3	82
33	Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease. <i>International Journal of Laboratory Hematology</i> , 2019 , 41, 325-330	2.5	
32	Extracorporeal membrane oxygenation in acute massive pulmonary embolism: a case series and review of the literature. <i>Perfusion (United Kingdom)</i> , 2019 , 34, 22-28	1.9	34
31	Thromboembolic Risk of 4-Factor Prothrombin Complex Concentrate versus Fresh Frozen Plasma for Urgent Warfarin Reversal in the Emergency Department. <i>Western Journal of Emergency Medicine</i> , 2019 , 20, 619-625	3.3	11
30	Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients. <i>Vascular Health and Risk Management</i> , 2019 , 15, 175-186	4.4	14
29	Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism. <i>Blood</i> , 2019 , 134, 2429-2429	2.2	0
28	Urban-Rural Variation in Use of Thrombolytic Therapy for Pulmonary Embolism. <i>Blood</i> , 2019 , 134, 3409-3409		
27	Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 31-40	5.1	45
26	Multicenter Implementation of a Novel Management Protocol Increases the Outpatient Treatment of Pulmonary Embolism and Deep Vein Thrombosis. <i>Academic Emergency Medicine</i> , 2019 , 26, 657-669	3.4	15
25	Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 117, 44-49	5.9	11
24	Treatment of submassive and massive pulmonary embolism: a clinical practice survey from the second annual meeting of the Pulmonary Embolism Response Team Consortium. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 46, 39-49	5.1	12
23	Pulmonary Embolism Response Team: Inpatient Structure, Outpatient Follow-up, and Is It the Current Standard of Care?. <i>Clinics in Chest Medicine</i> , 2018 , 39, 621-630	5.3	9
22	Contemporary Management and Outcomes of Patients with Massive and Submassive Pulmonary Embolism. <i>American Journal of Medicine</i> , 2018 , 131, 1506-1514.e0	2.4	42
21	Venous Thromboembolism: A Survey of Oral Anticoagulant Preferences in the Treatment of Challenging Patient Populations. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018 , 24, 209S-216S	3.3	2

20	The creation and implementation of an outpatient pulmonary embolism treatment protocol. <i>Hospital Practice (1995)</i> , 2017 , 45, 123-129	2.2	8
19	Nuts and bolts of running a pulmonary embolism response team: results from an organizational survey of the National PERT Consortium members. <i>Hospital Practice (1995)</i> , 2017 , 45, 76-80	2.2	20
18	Impact of Pulmonary Arterial Clot Location on Pulmonary Embolism Treatment and Outcomes (90Days). <i>American Journal of Cardiology</i> , 2017 , 119, 802-807	3	11
17	Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants. <i>Techniques in Vascular and Interventional Radiology</i> , 2017 , 20, 141-151	2.6	6
16	Case 40-2017. A 32-Year-Old Woman with Headache, Abdominal Pain, Anemia, and Thrombocytopenia. <i>New England Journal of Medicine</i> , 2017 , 377, 2581-2590	59.2	0
15	Comparison of Emergency Department Patients to Inpatients Receiving a Pulmonary Embolism Response Team (PERT) Activation. <i>Academic Emergency Medicine</i> , 2017 , 24, 814-821	3.4	11
14	Relation Among Clot Burden, Right-Sided Heart Strain, and Adverse Events After Acute Pulmonary Embolism. <i>American Journal of Cardiology</i> , 2016 , 118, 1568-1573	3	22
13	The Outpatient Treatment of Venous Thromboembolism: Operational Impact and the Role of Novel Anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2016 , 42, 846-856	5.3	5
12	A Multidisciplinary Pulmonary Embolism Response Team: Initial 30-Month Experience With a Novel Approach to Delivery of Care to Patients With Submassive and Massive Pulmonary Embolism. <i>Chest</i> , 2016 , 150, 384-93	5.3	131
11	Multidisciplinary pulmonary embolism response teams and systems. <i>Cardiovascular Diagnosis and Therapy</i> , 2016 , 6, 662-667	2.6	13
10	Diversity in the Pulmonary Embolism Response Team Model: An Organizational Survey of the National PERT Consortium Members. <i>Chest</i> , 2016 , 150, 1414-1417	5.3	48
9	A comparison of patients diagnosed with pulmonary embolism who are ≥ 5 years with patients. <i>American Journal of Cardiology</i> , 2015 , 115, 681-6	3	11
8	Genotyping lung cancer is an investment in the future. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3576-7	2.2	5
7	Case records of the Massachusetts General Hospital. Case 36-2013. A 38-year-old woman with anemia and thrombocytopenia. <i>New England Journal of Medicine</i> , 2013 , 369, 2032-43	59.2	5
6	Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. <i>British Journal of Haematology</i> , 2013 , 160, 351-8	4.5	16
5	Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). <i>British Journal of Haematology</i> , 2013 , 160, 530-7	4.5	97
4	Warfarin-induced skin necrosis in a patient with heparin-induced thrombocytopenia: two diseases or one?. <i>Acta Haematologica</i> , 2008 , 120, 117-22	2.7	8
3	The Incidence of Thrombosis in Patients with Isolated Heparin Induced Thrombocytopenia.. <i>Blood</i> , 2006 , 108, 1049-1049	2.2	1

2	The Identification of Hypercoagulable Markers in Patients with Malignant Gliomas and Venous Thromboembolism.. <i>Blood</i> , 2006 , 108, 4097-4097	2.2	1
1	Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management. <i>Hematology/Oncology Clinics of North America</i> , 2005 , 19, 183-202, vii	3.1	50